{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-02T01:41:26.172807+00:00","company":{"ticker":"RXRX","cik":1601830,"company_name":"RECURSION PHARMACEUTICALS, INC."},"pagination":{"limit":100,"returned":11,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"ad9a4bca2d17c99e13a01442623d05ba11d1e136","cik":1601830,"ticker":"RXRX","company_name":"RECURSION PHARMACEUTICALS, INC.","filed_at":"2026-05-06T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"first quarter ended March 31, 2026","report_date":"2026-05-06","result_type":"reported_results","revenue_text":null},"claim":"RECURSION PHARMACEUTICALS, INC. updated its first quarter ended March 31, 2026 guidance (reaffirmed).","evidence_excerpt":"today reported business updates highlighting strong continued pipeline execution, clinical progress and platform advancement, as well as financial results for its first quarter ended March 31, 2026.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001601830-26-000077","anchor_url":"https://secwatch.observer/filing/0001601830-26-000077#claim-ad9a4bca2d17c99e13a01442623d05ba11d1e136","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183026000077/0001601830-26-000077-index.htm"},{"fact_type":"executive_change","fact_key":"bb1e1b4d0a","cik":1601830,"ticker":"RXRX","company_name":"RECURSION PHARMACEUTICALS, INC.","filed_at":"2026-04-30T23:59:59+00:00","payload":{"action":"will not stand for re-election","action_category":"departure","departure_tone":"routine","effective_date":"2026-06-01","interim":false,"role":"Chair of the Board of Directors","role_category":"chair","successor_name":null,"successor_named":false},"claim":"Christopher Gibson departed as Chair of the Board of Directors at RECURSION PHARMACEUTICALS, INC..","evidence_excerpt":"On April 28, 2026, Christopher Gibson, Ph.D., Chair of the Board of Directors (the “Board”) of Recursion Pharmaceuticals, Inc. (the “Company”) and a member of the Research and Development Committee, Technology Committee, and the Corporate Social Responsibility Committee of the Board, informed the Company that he will not stand for re-election to the Board as a Class II Director at the 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”).","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001601830-26-000064","anchor_url":"https://secwatch.observer/filing/0001601830-26-000064#claim-bb1e1b4d0a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183026000064/0001601830-26-000064-index.htm"},{"fact_type":"restructuring_charge","fact_key":"2ab723ce50dcb900ce70f0d88f74ea59a22aa8ca","cik":1601830,"ticker":"RXRX","company_name":"RECURSION PHARMACEUTICALS, INC.","filed_at":"2025-06-10T23:59:59+00:00","payload":{"affected_area":null,"charge_text":"approximately $11 million","effective_date":"2025-06-10","event_type":"restructuring","headcount_text":"approximately 20%","item_codes_triggered":["2.05"]},"claim":"RECURSION PHARMACEUTICALS, INC. announced a restructuring with charges of approximately $11 million (approximately 20%).","evidence_excerpt":"into the fourth quarter of 2027. These changes are expected to result in a workforce reduction of approximately 20%. The Company estimates that it will incur approximately $11 million in charges in connection with the workforce reduction, consisting of severance payments, employee benefits, and related costs, substantially all of which the Company expects to","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-25-138138","anchor_url":"https://secwatch.observer/filing/0001193125-25-138138#claim-2ab723ce50dcb900ce70f0d88f74ea59a22aa8ca","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1601830/000119312525138138/0001193125-25-138138-index.htm"},{"fact_type":"executive_change","fact_key":"a237a18340","cik":1601830,"ticker":"RXRX","company_name":"RECURSION PHARMACEUTICALS, INC.","filed_at":"2025-03-18T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-03-15","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Dr. Namandjé Bumpus was appointed as Director at RECURSION PHARMACEUTICALS, INC..","evidence_excerpt":"The Board appointed Dr. Bumpus as a Class III Director of the Board, with her initial term to extend until the 2027 Annual Meeting of Stockholders, and appointed her as a member of the Nominating Committee of the Board, the Research and Development Committee of the Board, and the Technology Committee of the Board.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001601830-25-000040","anchor_url":"https://secwatch.observer/filing/0001601830-25-000040#claim-a237a18340","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183025000040/0001601830-25-000040-index.htm"},{"fact_type":"executive_change","fact_key":"03be3c1dd6","cik":1601830,"ticker":"RXRX","company_name":"RECURSION PHARMACEUTICALS, INC.","filed_at":"2025-03-18T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-03-15","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Elaine Sun was appointed as Director at RECURSION PHARMACEUTICALS, INC..","evidence_excerpt":"The Board appointed Ms. Sun as a Class III Director of the Board, with her initial term to extend until the 2027 Annual Meeting of Stockholders, and appointed her as the Chair of the Audit Committee of the Board and as a member of the Compensation Committee of the Board.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001601830-25-000040","anchor_url":"https://secwatch.observer/filing/0001601830-25-000040#claim-03be3c1dd6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183025000040/0001601830-25-000040-index.htm"},{"fact_type":"executive_change","fact_key":"6de626c02f","cik":1601830,"ticker":"RXRX","company_name":"RECURSION PHARMACEUTICALS, INC.","filed_at":"2024-11-20T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-11-20","interim":false,"role":"Class II Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Franziska Michor was appointed as Class II Director at RECURSION PHARMACEUTICALS, INC..","evidence_excerpt":"the Board increased the number of members of the Board from 7 to 8 and appointed Franziska Michor, Ph.D., (“Dr. Michor”) as a Class II Director of the Board","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001601830-24-000217","anchor_url":"https://secwatch.observer/filing/0001601830-24-000217#claim-6de626c02f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183024000217/0001601830-24-000217-index.htm"},{"fact_type":"executive_change","fact_key":"9c574936b8","cik":1601830,"ticker":"RXRX","company_name":"RECURSION PHARMACEUTICALS, INC.","filed_at":"2024-11-20T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-11-20","interim":false,"role":"Chief Financial Officer of the Company and President of Recursion UK","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Ben Taylor was appointed as Chief Financial Officer of the Company and President of Recursion UK at RECURSION PHARMACEUTICALS, INC..","evidence_excerpt":"Ben Taylor On November 20, 2024, the Board appointed Ben Taylor (“Mr. Taylor”), age 47, as Chief Financial Officer of the Company and President of Recursion UK, effective as of November 20, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001601830-24-000217","anchor_url":"https://secwatch.observer/filing/0001601830-24-000217#claim-9c574936b8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183024000217/0001601830-24-000217-index.htm"},{"fact_type":"executive_change","fact_key":"68fa937456","cik":1601830,"ticker":"RXRX","company_name":"RECURSION PHARMACEUTICALS, INC.","filed_at":"2024-11-20T23:59:59+00:00","payload":{"action":"transitioned from","action_category":"role_change","departure_tone":"routine","effective_date":"2024-11-20","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":"Ben Taylor","successor_named":true},"claim":"Michael Secora changed role as Chief Financial Officer at RECURSION PHARMACEUTICALS, INC..","evidence_excerpt":"Michael Secora On November 20, 2024, the Company announced that Michael Secora (“Dr. Secora”), Chief Financial Officer of the Company, will be transitioning from his role as Chief Financial Officer, effective as of November 20, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001601830-24-000217","anchor_url":"https://secwatch.observer/filing/0001601830-24-000217#claim-68fa937456","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183024000217/0001601830-24-000217-index.htm"},{"fact_type":"executive_change","fact_key":"bdf5c2d098","cik":1601830,"ticker":"RXRX","company_name":"RECURSION PHARMACEUTICALS, INC.","filed_at":"2024-08-08T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-08-12","interim":false,"role":"Director and Chair of Audit Committee","role_category":"director","successor_name":"Zachary Bogue","successor_named":true},"claim":"Terry-Ann Burrell resigned as Director and Chair of Audit Committee at RECURSION PHARMACEUTICALS, INC..","evidence_excerpt":"On August 6, 2024, Terry-Ann Burrell informed the Company’s board of her decision to resign as a member of the Company’s board and Chair of its Audit Committee, effective August 12, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-24-196505","anchor_url":"https://secwatch.observer/filing/0001193125-24-196505#claim-bdf5c2d098","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1601830/000119312524196505/0001193125-24-196505-index.htm"},{"fact_type":"executive_change","fact_key":"7f1974c52b","cik":1601830,"ticker":"RXRX","company_name":"RECURSION PHARMACEUTICALS, INC.","filed_at":"2024-05-24T23:59:59+00:00","payload":{"action":"elected as","action_category":"role_change","departure_tone":"not_applicable","effective_date":null,"interim":false,"role":"Chair of the Board","role_category":"chair","successor_name":null,"successor_named":false},"claim":"Robert Hershberg changed role as Chair of the Board at RECURSION PHARMACEUTICALS, INC..","evidence_excerpt":"the Board elected Robert Hershberg, M.D., Ph.D. as the Chair of the Board, effective at the 2024 Annual Meeting","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001601830-24-000065","anchor_url":"https://secwatch.observer/filing/0001601830-24-000065#claim-7f1974c52b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183024000065/0001601830-24-000065-index.htm"},{"fact_type":"executive_change","fact_key":"8b43d837e6","cik":1601830,"ticker":"RXRX","company_name":"RECURSION PHARMACEUTICALS, INC.","filed_at":"2024-05-24T23:59:59+00:00","payload":{"action":"will no longer stand for re-election","action_category":"departure","departure_tone":"routine","effective_date":null,"interim":false,"role":"Chair of the Board","role_category":"chair","successor_name":"Robert Hershberg","successor_named":true},"claim":"R. Martin Chavez departed as Chair of the Board at RECURSION PHARMACEUTICALS, INC..","evidence_excerpt":"R. Martin Chavez, Ph.D., Chair of the Board and member of the Audit Committee of the Board, informed the Company that he will no longer stand for re-election to the Board as a Class III Director at the 2024 Annual Meeting of Stockholders","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001601830-24-000065","anchor_url":"https://secwatch.observer/filing/0001601830-24-000065#claim-8b43d837e6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183024000065/0001601830-24-000065-index.htm"}]}